Limited lenalidomide exposure and access to rescue plerixafor can eliminate haemopoietic progenitor cell collection failure in multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone.

This retrospective single-centre study assessed sequential strategies to improve the success rate for haemopoietic progenitor cell mobilisation in multiple myeloma. Transplant-eligible multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone experience a mobilisation failure rate of 32%. We show that a combination of limiting lenalidomide exposure to less than 6 weeks and access to rescue plerixafor can eliminate haemopoietic progenitor cell collection failure without compromising other collection parameters.